Video Sponsor:
Check out our upcoming conferences. Q1 is a leading provider of high level educational content for the medical device, diagnostic, pharmaceutical, life science, and healthcare industries.
At Q1 Productions, we are leaders in developing and delivering executive education in highly regulated industries. Our upcoming Medical Communications & Dissemination of Scientific Information and Pharmaceutical & Biotech Medical Affairs Pre-Launch Strategies Conferences provide medical affairs professionals the chance to participate in discussions in a safe, virtual setting. Join us this September to benchmark with peers, network with industry experts and collaborate on mutual challenges.
Zagazig University Randomized Controlled #Ivermectin Study Results Confirms PI Hypothesis: Drug Effective Against #COVID19:
A principal investor from #ZagazigUniversity, Dr. Waheed Shouman, recently completed a randomized, open label, interventional trial titled “Use of Ivermectin as Prophylactic Option in Asymptomatic Family Close Contact for Patient with COVID-19.” Targeting 340 participants, this study was completed in late August. This included a total of 304 participated, 203 participants in the ivermectin group and 101 in the control group. The goal of this investigation was to determine whether ivermectin could serve as a prophylactic and included a 14 day follow-up period involving a diagnosis for symptoms of COVID-19.
Remdesivir Use in Multi-National Clinical Trial of Patients with Moderate COVID-19 & Pneumonia: Perplexing Results:
Remdesivir is the only therapy in the United States approved, under emergency use status, as a treatment for COVID-19 along with the just announced convalescent plasma. Referred to as not a ‘knockout drug’ by Dr. Anthony Fauci, Director of the National Institutes of Allergy and Infectious Diseases (NIAID), recently published outcomes from a multi-national and multi-academic medical center study had the potential to help turn what is frankly a question mark about the investigational drug into an exclamation point of confidence. The hope was that the antiviral offers a clear and compelling benefit to patients hospitalized with moderate COVID-19 pneumonia. Held at 105 hospitals, the study team treated 533 coronavirus patients with moderate pneumonia and randomized them to receive either remdesivir for 5 or 10 days or the standard of care from March 15 to April 18, 2020. While the drug showed a statistically significant benefit after a five-day course treatment, the group receiving the 10-day course of remdesivir received no statistically significant benefit in clinical status as compared with the standard of care at 11 days after onset of treatment.
Italian Led Observational Study Findings: Hydroxychloroquine Reduces COVID-19 Death Rate: Different Camps Emerge:
Yet another peer-reviewed observational study demonstrates that hydroxychloroquine contributes to the positive side of the argument for the use of this drug in the fight against COVID-19. However, the historical leanings don’t favor these antimalarial drug “camps” as the US Food and Drug Administration (FDA) withdrew emergency use authorization, and a handful of important studies have found that the drug doesn’t have an impact. Yet the research continues. Not long ago, TrialSite reported on the Henry Ford Health System findings that the malaria drug cuts the COVID-19 death rates, yet nearly right after the announcement of the findings, Dr. Anthony Fauci bypassed any scientific dialogue with the premier Michigan health system and declared to members in Congress that the study was “flawed.”
